

論文内容の要旨

獣医学専攻

平成 26 年度博士課程進学

前原 都有子

指導教員 村田 幸久

Investigation of the role of Prostaglandin D₂ in asthma

(喘息におけるプロスタグランジン D₂ の役割解明)

Introduction

Allergic lung inflammation is a hallmark of asthma. Prostaglandin D₂ (PGD₂) is a lipid mediator that exerts its biological function through two distinct receptors: D prostanoid receptor (DP) and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). PGD₂ metabolite, 15-deoxy-delta-12,14-PGJ₂ (15d-PGJ₂) functions via peroxisome proliferator-activated receptor- γ (PPAR- γ)-dependent signaling. Although the concentration of prostaglandin D₂ (PGD₂) is elevated in the allergic lung tissue, its contribution in disease progression remains unclear. We attempted to clarify the role of PGD₂ in ovalbumin (OVA)-induced OVA model using hematopoietic PGD synthase (H-PGDS) deficient mice.

Methods: OVA was intranasally administered to OVA-sensitized wild-type (WT) and H-PGDS deficient mice to induce chronic allergic lung inflammation. Isolated bronchi were organ-cultured with lipopolysaccharide (LPS).

Results: Repeated administration of OVA induced respiratory failure which was accompanied by increased eosinophil infiltration and mucin production in WT mice lung. Gene deficiency of H-PGDS enhanced OVA-induced these manifestations and mRNA expression of tumor necrosis factor- α (TNF- α) and eosinophil chemoattractants including Rantes and eotaxin-1. Immunostaining showed that bronchial epithelial cells strongly expressed H-PGDS and TNF- α in the inflamed WT lung. In cultured bronchus tissue of WT, LPS stimulation increased the mRNA expression of Rantes and eotaxin-1. H-PGDS inhibition promoted LPS-induced mRNA expressions of these chemokines further, which were inhibited by PGD₂ receptor agonist or PGD₂ metabolite, 15-Deoxy-Delta-12,14-PGJ₂ (15d-PGJ₂) pretreatment. Pretreatment with TNF receptor antibody inhibited eosinophil chemoattractant expression. *In vivo*, continuous administration of PGD₂ receptor agonist or 15d-PGJ₂ also attenuated the OVA-induced allergic lung inflammation in WT mice.

Conclusion: Bronchial epithelium-derived PGD₂ acts as a negative regulator by inhibiting the expression of TNF- α and chemoattractants in asthma.

The present findings indicate that enhancement of PGD₂/DP signaling and/or 15d-PGJ₂ treatment may exert therapeutic effects in asthma.